BioArctic AB Class B (DE:B9A)
FRANKFURT:B9A
B9A Stock Chart & Stats
€28.52
-€0.37(-2.00%)
At close: 4:00 PM EST
€28.52
-€0.37(-2.00%)
Day’s Range― - ―
52-Week Range€15.75 - €34.96
Previous CloseN/A
Volume0.00
Average Volume (3M)292.00
Market Cap
€2.59B
Enterprise Value€30.06B
Total Cash (Recent Filing)€2.03B
Total Debt (Recent Filing)€40.74M
Price to Earnings (P/E)130.8
Beta0.52
Next Earnings
Aug 26, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding74,324,486
10 Day Avg. Volume102
30 Day Avg. Volume292
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.22
Revenue Forecast (FY)€105.88M
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthVery low leverage and materially growing equity provide durable financial flexibility to fund R&D, absorb clinical setbacks and maintain operations without urgent financing. A strong balance sheet reduces insolvency risk and supports long-term program advancement and partnership negotiating power.
Improved Cash GenerationRecent operating cash flow well above net income in 2025 and TTM signals improved earnings quality and internal funding capacity. Sustained positive cash generation supports milestone work and reduces near-term dilution risk, enabling strategic investment in clinical programs and partnering activities.
Partnership/licensing Business ModelA partnership-focused model outsources late-stage development and commercialization to larger pharma, lowering capital intensity and commercialization risk. Milestones and royalties provide asymmetric upside tied to partner success, allowing BioArctic to monetize IP while focusing on R&D.
Bears Say
Volatile Revenue And EarningsLarge swings from losses to strong profits and a steep TTM revenue decline make forecasting and capital planning difficult. Milestone-driven income produces lumpiness that undermines predictability of recurring cash flow, increasing execution and valuation risk over the medium term.
Dependence On PartnersHeavy reliance on partner actions transfers critical execution and commercialization risk to third parties. If major partners like Eisai face regulatory, clinical or commercial setbacks, BioArctic’s milestone timing and royalty streams could be materially delayed or reduced, constraining growth.
Free Cash Flow InconsistencyZero FCF in 2025, a declining TTM FCF and prior negative years show inconsistent cash conversion. That volatility can limit reinvestment in early programs or force external funding at unfavorable terms, increasing dilution risk and constraining strategic optionality over time.
BioArctic AB Class B News
B9A FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was €15.75 and its highest was €34.96 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is €2.59B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is Aug 26, 2026 which is in 83 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on May 20, 2026. The company reported €0.22 earnings per share for the quarter, beating the consensus estimate of -€0.028 by €0.248.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B does not currently pay dividends.
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is -0.03.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,324,486 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of €0.22 in its last earnings report, beating expectations of -€0.028. Following the earnings report the stock price went up 1.716%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in DE:B9A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---